Context Therapeutics (NASDAQ:CNTX) Earns Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX) in a research note released on Friday,Benzinga reports. D. Boral Capital currently has a $9.00 price objective on the stock.

A number of other equities research analysts have also commented on the company. Citizens Jmp upgraded Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. JMP Securities began coverage on Context Therapeutics in a research report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Context Therapeutics in a report on Friday. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Context Therapeutics currently has an average rating of “Buy” and an average price target of $6.17.

Context Therapeutics Trading Up 0.2 %

Shares of NASDAQ CNTX opened at $0.77 on Friday. Context Therapeutics has a one year low of $0.64 and a one year high of $2.75. The firm has a market capitalization of $57.88 million, a PE ratio of -0.85 and a beta of 2.06. The business has a 50-day moving average price of $0.85 and a two-hundred day moving average price of $1.43.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. Research analysts anticipate that Context Therapeutics will post -0.51 EPS for the current year.

Institutional Investors Weigh In On Context Therapeutics

Several institutional investors have recently made changes to their positions in the company. Jane Street Group LLC bought a new position in Context Therapeutics in the 4th quarter worth $29,000. Citadel Advisors LLC bought a new position in Context Therapeutics in the 4th quarter worth $31,000. Shay Capital LLC bought a new position in Context Therapeutics in the 4th quarter worth $52,000. Clear Harbor Asset Management LLC raised its holdings in Context Therapeutics by 60.6% in the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock worth $61,000 after acquiring an additional 21,804 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new position in Context Therapeutics in the 3rd quarter worth $89,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.